- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- TScan Therapeutics Announces Closing of Upsized Public Offering
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
- TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.22 |
---|---|
High | 9.65 |
Low | 9.17 |
Bid | 9.26 |
Offer | 10.50 |
Previous close | 9.28 |
Average volume | 217.69k |
---|---|
Shares outstanding | 52.86m |
Free float | 48.17m |
P/E (TTM) | -- |
Market cap | 490.57m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼